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It has long been known that implantable cardioverter deﬁ-
brillator (ICD) shocks, although potentially lifesaving, can
produce a wide range of adverse psychological effects
including acute pain, anxiety, and depression (1). More
recently there has been increasing evidence that ICD shocks
may have direct adverse effects on myocardial function
leading to an increased risk of death. In the 2 largest studies
that established a mortality beneﬁt for ICD implantation for
the primary prevention of sudden death, the MADIT II
(Multicenter Automatic Deﬁbrillator Implantation trial II)
(2) and the SCD-HeFT (Sudden Cardiac Death in Heart
Failure Trial) (3), there was a paradoxical association between
receiving shocks and a subsequent 2 to 5 times increase inSee page 1343risk of death (4,5). This association between ICD shocks
and an increased risk of death is especially troublesome for
shocks that are triggered by rhythms other than ventricular
tachycardia (VT) or ventricular ﬁbrillation (VF). These
inappropriate shocks are not an uncommon occurrence. In
SCD-HeFT, 17% patients received inappropriate shocks
compared to 22.4% who received appropriate shocks over
a median of 45.5 months of follow-up (5). Similarly in
MADIT-II, 13% of patients had inappropriate shocks
during 2 years of follow-up (4). In these studies, the most
common cause of inappropriate shocks in decreasing order of
frequency were atrial ﬁbrillation; supraventricular tachycardia
such as sinus tachycardia, atrial tachycardias, and paroxysmal
supraventricular tachycardias; and oversensing caused by lead
fracture, T wave sensing, and electromagnetic interference.
The prevention of inappropriate shocks has been approached
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this paper to disclose.pass, ICD therapy is triggered by the patient’s heart rate going
above a programmed rate for a programmed duration. At
a second level, “discriminators” can be programmed to with-
hold therapy if, for instance, the heart rhythm is in the range for
VT but is irregular, suggesting atrial ﬁbrillation, or if the
electrogram recorded by the ICD looks identical to that
recorded in sinus, suggesting supraventricular tachycardia. Not
having the atrial ﬁbrillation discriminator programmed on was
associated with an increased risk of inappropriate shocks in
MADIT-II (4). More recently, prospective randomized trials
have shown that by programming the ICD to deliver therapy
only for relatively rapid heart rates of 188 to 200 beats/min or
more or by requiring the heart rate to stay fast for longer than
has been conventionally been programmed that the rate of
inappropriate therapy can be signiﬁcantly reduced with hazard
ratios (HR) as low as 0.21 (95% conﬁdence interval [CI]: 0.13
to 0.34) without an increased risk of syncope (6,7). In one of
those trials, MADIT-RIT (Multicenter Automatic Deﬁbril-
lator Implantation Trial-Reduce Inappropriate Therapy) (6),
prevention of inappropriate therapy by these programming in-
terventions produced a signiﬁcant reduction in all-cause
mortality in the range of 50%. This result suggests that inap-
propriate shocks may well directly increase mortality and
highlights the importance of all interventions thatmight prevent
inappropriate shocks.
Drug therapy also has the potential to reduce the risk of
inappropriate therapy. Beta-blockers can slow ventricular
rate in atrial ﬁbrillation, reducing the risk that the heart rate
will rise into the ICD therapy zone. Similarly, beta-blockers
reduce the maximum sinus rate, reducing the risk that sinus
tachycardia will trigger ICD shocks. Finally, beta-blockers
may prevent supraventricular tachycardia like AV node
reentry tachycardia and ectopic atrial tachycardia, thus
further reducing the risk of inappropriate ICD therapy.
In this issue of the Journal, Ruwald et al. (8) use data from
the MADIT-CRT (Multicenter Automatic Deﬁbrillator
Implantation Trial with Cardiac Resynchronization Therapy)
study (9) to compare the efﬁcacy of the beta-blockers car-
vedilol and metoprolol for the prevention of inappropriate
ICD therapy. In MADIT-CRT, patients receiving optimal
medical therapy who had class I or II congestive heart failure
and an ejection fraction less than or equal to 0.30 and a wide
QRS were randomized to implantation of a standard ICD or
a CRT-ICD. In this retrospective analysis, carvedilol was
found to be associated with a signiﬁcantly reduced risk of any
type of inappropriate ICD therapy (HR: 0.64 [95% CI: 0.48
to 0.85], p ¼ 0.002). Because the ﬁrst therapy programmed
in most ICDs is not shock but instead a burst of pacing
designed to terminate VT by disrupting the reentry VT
circuit, the authors also did an analysis restricted to ICD
shocks. This analysis showed inappropriate shocks were
signiﬁcantly less likely to occur in patients treated with car-
vedilol compared to those treated with metoprolol (HR: 0.54
[95% CI: 0.36 to 0.80], p ¼ 0.002).
Carvedilol is distinguished from metoprolol in that it
blocks alpha-1, beta-1, and beta-2 receptors, whilemetoprolol
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carvedilol has been shown to have antioxidant properties and
to inhibit several ion channels including the HERG-
associated potassium channel, the L-type calcium channel,
and the rapid-depolarizing sodium channel (10). Also, car-
vedilol has more potent antiadrenergic effects than meto-
prolol (11). Is there any reason to believe that these
differences might make carvedilol more effective at reducing
inappropriate shocks? A recent meta-analysis comparing
carvedilol to metoprolol and other beta-1 selective beta-
blockers showed that carvedilol was superior for the preven-
tion of all-cause mortality in heart failure patients (12). As all
MADIT-CRT patients had severe left ventricular dysfunc-
tion, it is reasonable to postulate that improved control of
heart failure might make atrial ﬁbrillation and other supra-
ventricular tachycardias less likely to occur. Looking speciﬁ-
cally at atrial ﬁbrillation, a recent meta-analysis showed that
carvedilol was superior to metoprolol for prevention of atrial
ﬁbrillation after open heart surgery (13). It is also possible
that carvedilol’s more potent antiadrenergic activity might
reduce the risk that a rapid ventricular response to atrial
ﬁbrillation will trigger ICD therapy. Finally, an analysis of
mortality, heart failure hospitalization, and therapy for VT or
VF in MADIT-CRT showed superior outcomes with car-
vedilol compared to metoprolol, suggesting a consistent
beneﬁt for all triggers of ICD therapy (14).
Although the results of the study by Ruwald et al. (8) are
plausible, there are important weaknesses in the analysis. The
most signiﬁcantweakness is that thiswas a retrospective analysis
with the choiceofbeta-blockermadebytheattendingphysician.
Patients prescribed metoprolol were, among other differences,
more likely to be older, have ischemic heart disease, have had
prior revascularization, have hypertension, have been hospital-
ized in the year prior to enrollment and to have been enrolled
outside the United States. In addition, when the metoprolol
doses patients were takingwere converted to equivalent doses of
carvedilol, the dose was signiﬁcantly less than that taken by
patients receiving carvedilol. Robust statistical methods were
used to correct for these baseline differences, but the differences
are so profound that one must question whether statistical
methods can fully correct for them or if other unmeasured
differencemay bedriving the results.Another important issue is
that thestudypopulation inMADIT-CRTisnotrepresentative
of the wide range of patients with ICDs or even patients with
primary prevention ICDs in that they were all class I or class II,
all had wide QRSs, and half had CRT devices. It is certainly
possible that one or more of these characteristics favored carve-
dilol in this particular population of ICD patients out of
proportion to the ICD population as a whole.
In summary, there are very important adverse effects asso-
ciated with inappropriate ICD shocks, and physicians taking
care of patients with ICDs should use everymechanism at their
disposal to prevent inappropriate shocks. Recent studies have
shown that programming higher rates to trigger ICD therapy
and longer durations at the higher rates can signiﬁcantly reduce
the risk of inappropriate shocks. Beta-blockers are an integralpart of optimalmedical therapy for patients with ICDs and can
reduce the risk of inappropriate shocks by preventing or
slowing atrial ﬁbrillation and other supraventricular tachycar-
dias. Alhough the study by Ruwald et al. (8) suggests that
carvedilol may be superior to metoprolol for this purpose and
should prompt further investigation of the relative efﬁcacy of
the 2 drugs for this indication, the weaknesses inherent in
retrospective analyses should at present prevent these results
from being used to inﬂuence clinical decision making.
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